Repligen Corporation — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. The filing is an annual report, not a standalone Q4 filing; quarterly results are also disclosed. Repligen develops and sells bioprocessing technologies and consumables for biologic drug manufacturing, across filtration, chromatography, process analytics and proteins.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Total revenue | $366.3 million | $270.2 million | +35.5% |
| Gross margin | 57.2% | 55.9% | +1.3 percentage points |
| Operating income | $69.8 million | $36.1 million | +93.5% |
| Net income | $59.9 million | $21.4 million | +180.0% |
| Diluted EPS | $1.11 | $0.44 | Increased |
| Cash from operations | $62.6 million | $67.2 million | Down $4.6 million |
- Product revenue rose 35.6%. Filtration generated $174.9 million, chromatography $73.6 million, process analytics $33.3 million and proteins $80.7 million. Process analytics included a full year of C Technologies results in 2020 versus seven months in 2019.
- Gross margin excluding acquisition inventory step-up amortization was 57.4%, compared with 56.5% in 2019. Management cited revenue growth and favorable product mix, partly offset by higher manufacturing headcount.
- Q4 revenue was $108.6 million, versus $69.5 million in Q4 2019; Q4 net income was $19.7 million, versus $3.6 million. Q4 2020 gross profit was $60.5 million.
- Year-end cash and cash equivalents were $717.3 million, up from $528.4 million. Current assets were $902.4 million and current liabilities $319.0 million.
- Operating cash flow was $62.6 million; investing activities used $201.4 million, including $175.0 million net cash for acquisitions and $26.3 million in capital expenditures. Financing provided $305.9 million, primarily from the December stock offering.
- Convertible notes had $287.5 million principal and $243.7 million carrying value at year-end. The 0.375% notes are due 2024, but were classified as current because holders could convert in Q1 2021. Their disclosed year-end fair value was $501.0 million.
- Non-GAAP adjusted net income was $89.1 million, versus $52.5 million in 2019; adjusted EBITDA was $107.9 million, versus $71.1 million. These measures exclude specified acquisition-related and other items and are not GAAP results.
Material changes versus the prior year
- Management attributed growth to broad-based customer demand, including monoclonal antibody, gene therapy and COVID-19 vaccine and therapeutic programs. It stated that COVID-19 positively affected 2020 revenue.
- Repligen acquired EMT, NMS and ARTeSYN in 2020 to expand single-use components, filtration and chromatography systems. The acquisitions contributed $6.2 million of additional filtration revenue during the periods owned; acquisition accounting also increased goodwill and intangible assets.
- The company raised approximately $297.8 million net through a December 2020 common-stock offering. Shares outstanding increased to 54.8 million at year-end from 52.1 million.
- MilliporeSigma represented 11% of 2020 revenue, down from 13% in 2019. Cytiva, a major customer in prior years, was no longer reported at 10% or more of 2020 revenue. Management said Cytiva moved part of its Protein A ligand manufacturing in-house during 2020.
Outlook, risks and notable items
- Management expected continued growth in direct sales in 2021, particularly as COVID-19 customers scale vaccine and therapy candidates through clinical processes. This is forward-looking commentary, not quantified revenue guidance.
- Management expected 2021 operating expenses to increase as the business expands and R&D expense to rise modestly. It said existing cash was adequate for at least 24 months absent acquisitions, while noting that lower demand or acquisition financing needs could change capital requirements.
- Key risks include dependence on a limited number of customers and suppliers, manufacturing capacity and timely delivery, competitive pressure, acquisition integration and valuation, foreign-exchange movements, and uncertainty about the duration and effects of COVID-19. The company reported 30% of 2020 revenue and 7% of costs and expenses denominated in foreign currencies and did not hedge this exposure.
- The company disclosed that its ATF patent expired in 2020 and said it was developing technology intended to mitigate potential effects. It also disclosed voluntary self-disclosures to the U.S. Department of Commerce concerning potential past exports without required licenses; consequences, if any, could include penalties or other restrictions.
- The 2020 acquisition purchase-price allocations were preliminary, and final adjustments could be material. The independent auditor identified acquisition valuation, including assumptions used for acquired customer relationships and technology, as a critical audit matter.
- No legal proceedings were identified that management believed would have a material adverse effect. Management and the auditor reported effective internal control over financial reporting; the acquired 2020 businesses were excluded from the year-end controls assessment under the SEC’s recently acquired business guidance.
Important facts for investors to verify
- How much of 2020 growth reflected underlying demand versus COVID-19-related orders, acquisitions and the full-year contribution from C Technologies.
- Whether elevated customer demand and revenue growth continue, and how customer concentration and Cytiva’s in-house production affect Protein A sales.
- The final acquired-asset valuations and realized benefits from EMT, NMS and ARTeSYN, including integration costs and goodwill or intangible-asset impairment exposure.
- How holders’ conversion activity for the $287.5 million notes affects cash needs, share dilution and future interest expense.
- Whether the company can convert revenue growth into operating cash flow as receivables and inventory increased, and whether manufacturing investments support demand without pressuring margins.
- Any outcomes or disclosures arising from export-control self-disclosures, supplier constraints, COVID-19 developments or expiration of the ATF patent.